Cogo R, Monzani G P, Fusillo M, Vota M
USSL n. 60 Presidio Ospedaliero di Ornago, Milano.
Minerva Med. 1991 Mar;82(3):115-8.
We studied the clinical and instrumental modifications of 20 patients (mean age: 67.95 +/- 1.23 years; 13 males, 7 females) suffering from COPD (less than 65% theoretical FEV1), during treatment with bamiphylline. At basal time, and after 1, 2, 3, 4, and 6 months of therapy we performed a clinical and spirometric examination. All spirometric parameters (FEV1, VC, MEF25-75, Tiffeneau Index) increased significantly (p less than 0.01 - ANOVA1) since the first control performed after 1 month of treatment. This trend was confirmed in the successive controls. Analogue results were observed for emogasanalytical (P-CO2-PO2) and clinical (cough and dyspnoea) parameters. During the experimental research we did not observe side effects due to the xanthine-derivative (bamiphylline) under study or modifications of the main haematochemical tests. Therefore we believe that bamiphylline must be considered an effective therapeutic tool for COPD therapy.
我们研究了20例慢性阻塞性肺疾病(COPD,预计第一秒用力呼气容积(FEV1)低于65%)患者(平均年龄:67.95±1.23岁;男性13例,女性7例)在接受巴米茶碱治疗期间的临床和仪器检查结果变化。在基线期以及治疗1、2、3、4和6个月后,我们进行了临床和肺功能检查。自治疗1个月后首次进行检查起,所有肺功能参数(FEV1、肺活量(VC)、最大呼气中期流速(MEF25 - 75)、蒂芬诺指数)均显著升高(p<0.01 - 单因素方差分析1)。这一趋势在后续检查中得到证实。对于气体分析(二氧化碳分压 - 氧分压)和临床(咳嗽和呼吸困难)参数也观察到类似结果。在实验研究期间,我们未观察到所研究的黄嘌呤衍生物(巴米茶碱)引起的副作用或主要血液生化检查结果的改变。因此,我们认为巴米茶碱必须被视为慢性阻塞性肺疾病治疗的一种有效治疗手段。